Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1/2a study of 3’UTRMYC1-18 in c-MYC-driven cancers
PACTR202609759515744Phase 1Not yet recruiting
- Sponsor
- UTR Therapeutics
- Start
- Feb 2027
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial in triple-negative breast cancer (TNBC), pancreatic cancer (PC), ovarian cancer and 1 more, sponsored by UTR Therapeutics. Primary endpoints: Treatment-emergent adverse events, Dose-limiting toxicities and 1 more. Planned start Feb 2027; status: not yet recruiting.
02
Conditions
triple-negative breast cancer (TNBC)pancreatic cancer (PC)ovarian cancercolon cancer
Beyond the preview
Go deeper on PACTR202609759515744.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202609759515744.